Seiichi Okabe

1.3k citations

92 papers · 969 indexed · h-index 18

Impact in

Hematology top 2%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 67
- Chronic Myeloid Leukemia Treatments 50
- Acute Myeloid Leukemia Research 21
Genetics 42
- Chronic Lymphocytic Leukemia Research 34
- Myeloproliferative Neoplasms: Diagnosis and Treatment 9

Co-authors: Kazuma Ohyashiki Tetsuzo Tauchi Junko H. Ohyashiki Yuko Tanaka Hal E. Broxmeyer Chiaki Kobayashi Seiichiro Katagiri Seiji Fukuda
Journals: Blood (29 papers)Experimental Hematology (3 papers)Oncotarget (3 papers)PLoS ONE (3 papers)Clinical Cancer Research (2 papers)
Partner nations: Japan United States United Kingdom

In The Last Decade

Seiichi Okabe

87 papers receiving 953 citations

Peers

Countries citing papers authored by Seiichi Okabe

Since Specialization

Citations

This map shows the geographic impact of Seiichi Okabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiichi Okabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiichi Okabe more than expected).

Fields of papers citing papers by Seiichi Okabe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiichi Okabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiichi Okabe. The network helps show where Seiichi Okabe may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Seiichi Okabe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Seiichi Okabe Line = papers co-authored together Seiichi Okabe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combination of WEE1 Inhibitor and Vitamin K2 Enhances Therapeutic Efficacy in Chronic Myeloid Leukemia PubMed ·Seiichi Okabe, Ferry G. McCollom, Akihiko Gotoh, Daigo Akahane	2025	1
2	Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity International Journal of Molecular Sciences ·Seiichi Okabe, Ferry G. McCollom, Akihiko Gotoh	2024	1
3	Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway PLoS ONE ·Tetsuzo Tauchi, Shota Moriya, Seiichi Okabe, Hiromi Kazama, Keisuke Miyazawa, Naoharu Takano	2024	3
4	Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma Experimental Hematology and Oncology ·Seiichi Okabe, Yuko Tanaka, Akihiko Gotoh	2021	14
5	Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells Cancer Chemotherapy and Pharmacology ·Seiichi Okabe, Yuko Tanaka, Yetunde Omoyiwola Fawehinmi, Akihiko Gotoh	2020	8
6	Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation Annals of Hematology ·Seiichi Okabe, Yuko Tanaka, Tetsuzo Tauchi, Kazuma Ohyashiki	2018	15
7	Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells Blood ·Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Kazuma Ohyashiki	2017	1
8	Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC) Blood ·Tetsuzo Tauchi, Seiichi Okabe, Seiichiro Katagiri, Yuko Tanaka, Kazuma Ohyashiki	2017	3
9	Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors International Journal of Hematology ·杨天宏, Tomohiro Umezu, Seiichiro Katagiri, Chiaki Kobayashi, Tetsuzo Tauchi, Moritaka Gotoh, Keiko Ando, Seiichi Okabe, Junko H. Ohyashiki, Kazuma Ohyashiki	2017	16
10	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia Molecular Cancer Therapeutics ·Atsushi Nemoto, Satoshi Saida, Itaru Kato, Jiro Kikuchi, Yusuke Furukawa, Yasuhiro Maeda, Koshi Akahane, K MacGaffey, Kumiko Goi, Keiko Kagami, Shinya Kimura, Yuko Sato, Seiichi Okabe, Akira Niwa, Kenichiro Watanabe, Tatsutoshi Nakahata, Toshio Heike, Kanji Sugita, Takeshi Inukai	2015	20
11	Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome–positive acute lymphoblastic leukemia Cytotherapy ·Shoji Saito, Yozo Nakazawa, Jeff D. Cohen, Kazuyuki Matsuda, Miyuki Tanaka, Ryu Yanagisawa, Yasuhiro Maeda, Yuko Sato, Seiichi Okabe, Takeshi Inukai, Kanji Sugita, Matthew H. Wilson, Cliona M. Rooney, Kenichi Koike	2014	42
12	A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies Bone Marrow Transplantation ·Moritaka Gotoh, Seiichiro Yoshizawa, Seiichiro Katagiri, Otto Lukat, 杨天宏, Carlos Alberto Ferreira, Daigo Akahane, Seiichi Okabe, Tetsuzo Tauchi, Yoshikazu Ito, Kazuma Ohyashiki	2014	2
13	Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia Clinical Cancer Research ·Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Yosuke Minami, Shinya Kimura, Taira Maekawa, Tomoki Naoe, Kazuma Ohyashiki	2013	35
14	Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation Cancer Biology & Therapy ·Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, M. Amjadi, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki	2013	32
15	Effects of the Hedgehog Inhibitor GDC-0449, Alone or in Combination with Dasatinib, on BCR-ABL-Positive Leukemia Cells Stem Cells and Development ·Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Seiichiro Katagiri, Kazuma Ohyashiki	2012	16
16	The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1 Cancer Science ·Junko H. Ohyashiki, Chiaki Kobayashi, Laura García López, Seiichi Okabe, Tetsuzo Tauchi, Kazuma Ohyashiki	2009	112
17	Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing Cell Lines and Cells from Patients with Chronic Myelogenous Leukemia in Blast Crisis Stem Cells and Development ·Seiichi Okabe, Tetsuzo Tauchi, Akihiro Nakajima, Goro Sashida, Akihiko Gotoh, Hal E. Broxmeyer, Junko H. Ohyashiki, Kazuma Ohyashiki	2007	29
18	Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors Oncogene ·H Li, Tetsuzo Tauchi, Tomoiku Takaku, Seiichi Okabe, Daigo Akahane, Goro Sashida, Junko H. Ohyashiki, Kazuma Ohyashiki	2007	16
19	Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor-β1 Leukemia & lymphoma ·Seiichi Okabe, Keisuke Miyazawa, Herdin Amri Gibrani, Masahiko Sumi, Tomoiku Takaku, Yoshikazu Ito, Yukihiko Kimura, Hiromi Serizawa, Kiyoshi Mukai, Kazuma Ohyashiki	2005	9
20	Src Kinase, but Not the Src Kinase Family Member p56 ^lck , Mediates Stromal Cell-Derived Factor 1α/CXCL12-Induced Chemotaxis of a T Cell Line Journal of Hematotherapy & Stem Cell Research ·Seiichi Okabe, Seiji Fukuda, Hal E. Broxmeyer	2002	13

About Seiichi Okabe

Seiichi Okabe is a scholar working on Hematology, Genetics, Rheumatology, Immunology and Allergy and Oncology, having authored 92 papers that have together received 969 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (50 papers), Chronic Lymphocytic Leukemia Research (34 papers), Acute Myeloid Leukemia Research (21 papers), Eosinophilic Disorders and Syndromes (12 papers), Protein Degradation and Inhibitors (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers), Hedgehog Signaling Pathway Studies (9 papers) and Histone Deacetylase Inhibitors Research (7 papers). The work is most often cited by research in Hematology (417 citations), Genetics (287 citations), Oncology (273 citations), Immunology (170 citations) and Molecular Biology (404 citations). Seiichi Okabe has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kazuma Ohyashiki, Tetsuzo Tauchi, Junko H. Ohyashiki, Yuko Tanaka, Hal E. Broxmeyer, Chiaki Kobayashi, Seiichiro Katagiri, Seiji Fukuda, Akihiko Gotoh and Shinya Kimura. Their work appears in journals such as Blood, Experimental Hematology, Oncotarget, PLoS ONE and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact